Email Us
Call Us
Bispecific antibodies bind two targets simultaneously. In oncology the dominant format engages a tumor antigen with one arm and CD3 on T cells with the other, forcing an immunological synapse between a T cell and a tumor cell independent of the T cell’s own antigen specificity. The mechanism is powerful and its principal liability follows directly from it: T-cell activation at scale produces cytokine release, which is the dose-limiting toxicity for this class.
Preclinical evaluation therefore has two objectives rather than one. Efficacy establishes that the molecule redirects T-cell killing to the tumor. Cytokine characterization establishes the dose at which it does so without producing release that would limit clinical use. A study measuring only tumor volume has addressed half the question, and the half that rarely stops a program.
Altogen Labs conducts bispecific antibody studies in humanized platforms with tumor response and cytokine release measured in the same animals. To discuss a study design, request a quote.
Platform requirements
A CD3-engaging bispecific requires human T cells, so a humanized platform is not optional. Peripheral blood reconstitution provides rapid T-cell engraftment and suits short studies where activity is expected quickly. CD34-positive reconstitution and the ATO-supported BLT platform support longer studies and broader immune representation.
Target antigen expression in the tumor model must match the intended clinical setting in kind and approximately in level, since redirected killing depends on antigen density and a model expressing target far above clinical levels will overstate both efficacy and the therapeutic window.
Therapeutic index rather than maximum efficacy
The useful output of a bispecific study is not the dose producing greatest tumor control but the dose producing adequate control with acceptable cytokine elevation. Those are different doses, and establishing the separation between them is the purpose of the study.
Dose-ranging designs with parallel efficacy and cytokine measurement define that relationship. Step-up dosing designs, where an initial lower dose precedes full dosing, test whether priming reduces cytokine release on subsequent administration, which is a strategy in clinical use and one that preclinical work can inform.
Cytokine sampling
Cytokine responses to T-cell engaging agents peak within hours of administration and resolve before a conventional next-day sample. A study sampling only at trough will record no response from a molecule that produced a substantial one, and will report a therapeutic window that does not exist.
Sampling is concentrated in the hours following the first dose, with the schedule set from expected kinetics or established in a pilot time course. Interferon gamma, interleukin 6, tumor necrosis factor alpha, and interleukin 2 are commonly included, extended as the mechanism requires.
Applied examples
Therapeutic index definition. A bispecific is administered across a dose range with tumor response and cytokines measured in parallel, identifying the dose at which tumor control is achieved at acceptable cytokine elevation rather than the dose producing maximum regression.
Step-up dosing. A priming dose precedes full dosing in one arm and not in another, with cytokine release after the full dose compared between arms to establish whether priming mitigates the response.
Antigen density dependence. The molecule is evaluated against tumor lines differing in target expression level, characterizing the density threshold below which redirected killing becomes ineffective.
Scope, format, and reporting
Altogen Labs evaluates antibodies supplied by the client. Antibody discovery, engineering, and production are not offered, and the service covers in vivo evaluation and the associated immune pharmacodynamics.
Reports state the reconstitution platform and donor source, target expression level in the model, cytokine sampling schedule, and per-animal values for both efficacy and cytokine endpoints, since group means obscure the individual variation that matters most when the question is a safety margin. All procedures are conducted under active IACUC protocols, with humane endpoints defined for treatment-related cytokine effects in addition to tumor burden. GLP standards are applied where a study is formally designated as GLP.
Send antibody format, target antigen, and expected clinical dose range, or request a quote.